BioVaxys Technology (XCNQ:BIOV) Tax Rate % : 0.00% (As of Jul. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. BioVaxys Technology's Tax Expense for the three months ended in Jul. 2024 was C$0.00 Mil. BioVaxys Technology's Pre-Tax Income for the three months ended in Jul. 2024 was C$-1.19 Mil. Therefore, BioVaxys Technology's Tax Rate % for the quarter that ended in Jul. 2024 was 0.00%.

BioVaxys Technology Tax Rate % Historical Data

The historical data trend for BioVaxys Technology's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Tax Rate % Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Tax Rate %

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Tax Rate %	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

BioVaxys Technology's Tax Rate % for the fiscal year that ended in Oct. 2023 is calculated as

Tax Rate %	=	Tax Expense (A: Oct. 2023 )	/	Pre-Tax Income (A: Oct. 2023 )
	=	0	/	-7.687
	=	0.00 %

BioVaxys Technology's Tax Rate % for the quarter that ended in Jul. 2024 is calculated as

Tax Rate %	=	Tax Expense (Q: Jul. 2024 )	/	Pre-Tax Income (Q: Jul. 2024 )
	=	0	/	-1.186
	=	0.00 %

BioVaxys Technology Tax Rate % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

BVAXF:USA 5LB:Germany

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Executives

James Passin	Director, Senior Officer
Kenneth Kovan	Senior Officer

BioVaxys Technology Headlines

No Headlines